PMS81 Cost-Effectiveness and Budget Impact of Certolizumab Pegol Against a Mix of Treatments in an Outcomes-Based Risk-Sharing Scheme in Finland
Nov 1, 2012, 00:00 AM
10.1016/j.jval.2012.08.1436
https://www.valueinhealthjournal.com/article/S1098-3015(12)03149-X/fulltext
Section Title :
Muscular-Skeletal Disorders
Section Order :
934
First Page :
A454
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(12)03149-X&doi=10.1016/j.jval.2012.08.1436